Research on the impact of technology mergers and acquisitions on corporate performance: an empirical analysis based on China's pharmaceutical industry

• Published in: Frontiers in public health Vol. 12; p. 1419305
• Main Authors: Yang, Jialin, Li, Jiawen, Wang, Su, Chen, Yuwen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 09.08.2024
• Subjects: China; corporate performance; Drug Industry; Empirical Research; Humans; Investments; mediating effects; pharmaceutical industry; R&D; technology M&A; China; corporate performance; mediating effects; R&D; pharmaceutical industry; technology M&A
• DOI: 10.3389/fpubh.2024.1419305
• ISSN: 2296-2565

There is intense competition among pharmaceutical companies with the rapid growth of the global pharmaceutical industry. In recent years, China has continuously increased the reform of the medical system. Technology mergers and acquisitions (M&A) in China's pharmaceutical industry have emerged in this complex policy and economic background. This paper conducts an empirical study from the dual perspectives of financial performance and innovation performance, based on unbalanced panel data of Chinese listed pharmaceutical firms from 2012 to 2022. The impact of technology M&A on firm performance is analyzed in terms of the heterogeneity of firm characteristics. Meanwhile, the relationship between R&D investment in technology M&A and firm performance is examined. The results show that technology M&A can promote the performance of pharmaceutical companies, and R&D investment has a mediating effect on the impact of technology M&A on corporate performance. Based on the above findings, this study enriches the relevant literature on technology M&A in the pharmaceutical industry, provides warnings and suggestions for pharmaceutical companies to improve corporate performance through technology M&A, and provides reference materials for future policy formulation.